XNAS · Healthcare · Diagnostics & Research
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | Q1 2026 | -0.50 | -0.49 | +2.00% | $83.7M | ✅ Beat | -0.61% | -26.67% | — |
| 2026-02-26 | Q4 2025 | -0.24 | -0.08 | +66.67% | $87.0M | ✅ Beat | +4.45% | -12.45% | -26.19% |
| 2025-11-03 |
| Q3 2025 |
| -0.44 |
| -0.02 |
| +95.45% |
| $83.0M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-02-27 | Q4 2024 | 0.04 | 0.32 | +700.00% | $86.3M | ✅ Beat | -14.24% | -18.55% | -20.81% |
| 2024-11-04 | Q3 2024 | -0.06 | 0.08 | +233.33% | $85.8M | ✅ Beat | -7.40% | +0.42% | -5.23% |
| 2024-05-02 | Q1 2024 | -0.33 | -0.09 | +72.73% | $73.0M | ✅ Beat | +6.52% | +6.92% | +2.45% |
| 2024-02-28 | Q4 2023 | -0.54 | -0.10 | +81.48% | $66.1M | ✅ Beat | -25.95% | -12.01% | -8.77% |
| 2023-11-02 | Q3 2023 | -0.76 | -0.26 | +65.79% | $61.5M | ✅ Beat | +7.99% | +2.88% | +19.82% |
Showing last 8 quarters.